Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label first-line study of Xeloda [capecitabine] in combination with cisplatin on overall treatment response in patients with metastatic nasopharyngeal cancer.

Next Previous
X
Search
Trial Profile

An open-label first-line study of Xeloda [capecitabine] in combination with cisplatin on overall treatment response in patients with metastatic nasopharyngeal cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 23 Jun 2010 Actual patient number changed from 42 to 45 as reported by Roche.
    • 19 Dec 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 01 Jun 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top